Pilot Research Project Core

试点项目核心 作为PACE的“实施”部门，试点项目核心将推动OUD的新发现，这些发现是 由PET成像技术独一无二地实现。试点项目将利用放射化学核心、成像核心和 临床核心和行政核心将支持培训和职业发展。具体目标是： (1)通过一系列相互关联和严谨的试验项目，加速大学科学的发展 利用PACE基础设施。初步审查的试点项目将阐明MU和三角洲的作用- 阿片受体可利用度及其治疗、遗传变异对受体可利用度的影响 和治疗剂量，(C)kappa-阿片受体在自杀意念中的作用，以及 无论是否感染艾滋病毒，神经炎症在OUD中的机制作用；(2)监督公平和透明的 征集、审查、支持和评估创新和严格的未来试点项目的流程。劳作 与行政核心一起，试点核心将从第二年开始每年征求申请，直到 直接联系宾夕法尼亚大学和耶鲁大学的部门和中心，并通过全校电子邮件；开展 科学严谨的NIH式内部审查流程，具有透明的优秀标准，提供跨学科 指导和支持，包括科学规划、方法和技术援助，并评价 这些努力的成功；以及(3)培养下一代成瘾PET成像科学家。这些 活动包括PET成像、数据分析和OUD神经生物学的授课和体验培训，以及 跨学科的共同指导和职业发展机会。培训计划将吸引和支持 早期研究人员和希望将PET成像纳入成瘾的成熟研究人员 研究。最后，一年一度的佩斯研究日将召集宾夕法尼亚大学活跃的PET研究人员，佩斯的 内部和外部咨询委员会，以及新的调查人员，以分享最新研究成果并 鼓励使用新的P30 PET工具进行协作。

PILOT PROJECT CORE As the “implementation” arm of the PACE, the Pilot Project Core will drive novel discoveries in OUD that are uniquely enabled by PET imaging. Pilot projects will leverage the Radiochemistry Core, Imaging Core, and Clinical Core, and the Administrative Core will support training and career development. The Specific Aims are: (1) to accelerate the science of OUD through a set of inter-related and rigorous pilot projects that leverage the PACE infrastructure. An initial set of vetted pilot projects will elucidate the role of mu- and delta- opioid receptor availability in OUD and its treatment, the influence of genetic variation on receptor availability and therapeutic dosing in OUD, (c) the role of the kappa-opioid receptor in suicidal ideation in OUD, and the mechanistic role of neuroinflammation in OUD with or without HIV; (2) to oversee a fair and transparent process to solicit, review, support, and evaluate innovative and rigorous future pilot projects. Working with the Administrative Core, the Pilot Core will solicit applications on an annual basis beginning in year 2 through direct outreach to Departments and Centers at Penn and Yale, and through campus-wide emails; conduct a scientifically rigorous internal NIH-style review process with transparent merit criteria, provide interdisciplinary mentoring and support, including scientific planning and methodological and technical assistance, and evaluate the success of these efforts; and (3) to train the next generation of addiction PET imaging scientists. These activities include didactic and experiential training in PET imaging, data analysis, and OUD neurobiology, and interdisciplinary co-mentorship and career development opportunities. Training initiatives will attract and support both early-stage investigators and established investigators who wish to incorporate PET imaging into addiction research. Finally, an annual PACE Research Day will convene Penn's active PET researchers, the PACE's Internal and External Advisory Boards, and new investigators to share the latest research findings and to encourage collaborations with the new P30 PET tools.